Prostate cancer uk

PCaSO Bournemouth Group

Notice of Dorset PCaSO Meeting

Public Meeting on

 Wednesday September 27th 2017 at 7.30 pm
St. Mark’s New Church Hall Wallisdown Road, Talbot Village, Bournemouth, BH10 4HY

Unfortunately our speaker who was to be Dr Joe Davis from Poole Hospital has had to cancel his talk to us. We will update you when we find an alternative speaker.

Last date for 2017

Our last meeting this year will be on Wednesday November 29th at 7.30 pm in St Mark’s NewChurch Hall.

PSA Tests

We have now tested over 3000 men in Dorset!

Our next session will be in Christchurch on Saturday 23rd September 2017. More details later.

Branch contact details

PCaSO Dorset Branch
6 Firside Road
Corfe Mullen,Wimborne
Dorset, BH21 3LS
Telephone: 01202 58043601202 696107
Helpline: 0800 035 5302

Our Local Committee

Chairman and Awareness / Lobbying: Jim Davis
Treasurer: Barry Taylor
Secretary and Publicity: Ray Bona
Membership Sec: Clive Duddridge
PSA Testing: Allan Higgin
Fund-raising: Brian Deacon
Speakers Organiser: Catherine Woolford
Website / Executive: Derek Pilling

The Link

Newsletter of PCaSO (Prostate Cancer Support Organisation)

Dorset Branch

July 2017

PSA Tests
We have now tested over 3000 men in Dorset!
Sessions are due to take place in Christchurch on Saturday 23rd September
with others, to be announced later, which are still being arranged.

become the preferred treatment for many cases of prostate cancer? Will a
test for the PCA3 gene supersede the present PSA test?

See article overleaf …..

Have you any suggestions for speakers’ topics at forthcoming meetings? And any suggestions as to speakers you would like to hear? If so, please let me (Ray Bona) know (see email addresses below).
See article overleaf …..

If you are able to assist with admin work at PSA Testing sessions (you need no special knowledge — just neat writing and an ability to pay attention to detail), please ring Jim Davis (01202 580436)

JULY 2017

“KNOWLEDGE EMPOWERS” – Sir Francis Bacon 1597

From website “”
This extract discusses use of proton beam therapy but applies to treatment in the USA – hence the concluding sentence!

The overwhelming majority of men newly diagnosed with prostate cancer have to decide on one of two options. One option is to not treat their prostate cancer and to engage in watchful waiting — the downside of this option is that it is not possible to determine if the type of cancer we develop is the serious type that could kill us. Thus, watchful waiting carries with it concern over not treating cancer that could be deadly. The other option is to treat their prostate cancer by selecting treatment with
risks of serious side effects, such as surgery or IMRT. The good news is that the answer to the prostate cancer conundrum is, in my opinion, in selecting a minimally invasive treatment such as proton therapy. Doing this will not only allow you to treat your prostate cancer in case you have the type that could kill you, it also does not expose you to the risk of serious side effects. Dr. Vorstman passionately encourages men to consider non-invasive treatments of prostate cancer when he
states: “Over the last few years, sophisticated advancements in several minimally invasive technologies such as cryoablation, radiation/proton, hifu and others have seriously questioned once more the very unfounded and controversial place of the heavy-handed, high-risk traditional surgical and robotic excision of prostate cancer. Time has made it quite clear that no amount of technology can circumvent the problems that necessarily result from the cutting out of your prostate.” Another potential way of solving the prostate cancer conundrum is a promising new test for
identifying men at risk of having aggressive prostate cancer involving analyzing urine for the presence of the PCA3 gene. Molecular diagnostics has resulted in a specific test for identifying the urinary PCA3 gene found to be related to the presence of deadly, aggressive prostate cancer. This test can be a valuable alternative to the PSA Test in that it has greater ability to identify the risk of
possessing deadly prostate cancer. If it becomes widely used as an alternative to the PSA, the goal of reducing the number of men referred for treatment with the risk of serious side effects can be achieved. If it does become widely used two consequences will occur: (1) fewer men will receive
treatment they don’t need and (2) the amount of money generated by unnecessary treatment will drastically reduce the profits of the prostate cancer industry. With this latter possibility in mind, don’t be surprised if a crescendo of criticism of this new test develops. Any threat to the huge profits generated by the way prostate cancer is now treated will not be well received.

To all email recipients IMPORTANT

If for some reason or other you have no further interest in receiving these bi-monthly newsletters, please let me know so that you can be removed from the circulation list.

You can email me at or at

Ray Bona
(Hon. Sec)